News & Updates

Use of zuranolone significantly improves depressive symptoms, with no serious side effects, in women with severe postpartum depression (PPD), a common perinatal complication with adverse maternal and infant outcomes, results of a phase III trial have shown.

Treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) appears to increase the risk of venous thromboembolism (VTE) in women using hormonal contraception, reveals a study.

In cancer patients with isolated distal deep vein thrombosis (IDDVT), a 12-month anticoagulation regimen with the oral factor Xa inhibitor edoxaban fared better than a 3-month regimen, findings from the ONCO DVT study have shown.

Treatment with low-dose spironolactone results in reduced albuminuria without causing hyperkalaemia in patients with type 2 diabetes (T2D), reports a study.

Faecal microbiota transplantation helps reduce abdominal bloating but not the overall symptoms in patients with irritable bowel syndrome (IBS), according to a small study.

The high clinical response levels achieved with bimekizumab over 48 weeks persist up to week 96 in patients with moderate-to-severe plaque psoriasis, results of the BE RADIANT phase IIIb trial have shown. In addition, those on secukinumab who switched to bimekizumab have achieved similar responses at 96 weeks.

In the treatment of patients with programmed cell death ligand 1 (PD-L1)-positive, unresectable, and locally advanced nonsmall cell lung cancer (NSCLC), the use of durvalumab immunotherapy in combination with curative radiotherapy yields survival gains with tolerable adverse events (AEs), as shown in the results of the phase II DOLPHIN trial.